Ontario Institute for Cancer Research Institute

awards grant

• A Clinical Chemistry Approach for Identifying Biomarkers as Surrogate Endpoints in Therapy directed against Chemokine meditated Metastasis
• A Multimodal and general-purpose Tumour Probe for Imaging, Biopsy and Surgical Guidance: Metastatic Potential Imaging by Targeting uPA
• A Phase I Study Investigating Multiple Injections of Autologous CD34+ Derived Dendritic Cells Transduced with an Adenovirus Expressing Rat Her-2/neu in Patients with Metastatic Breast Cancer
• A pilot study of BOLD MRI and FLT-PET in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy
• Assessment of New Molecular Imaging Strategies for Prostate Cancer (MISTER): Predictive Value of Established and Novel PET Radiotracers in Castration-Resistant Prostate Cancer
• Biomarkers to Aid Treatment Decision Making in Early Stage Breast Cancer in Ontario (BIANCO) - Economic analysis of the OncotypeDX field evaluation cohort study
• Cancer Stem Cell Program (McMaster)
• Cancer Stem Cells Program - Equipment Award for Mick Bhatia
• Centre for Probe Development and Commercialization (CPDC)
• Development and testing of a biophotonic platform for in vivo assessment of tumour progression and treatment efficacy
• Development of Radiolabeled Insulin Probe
• Development of a Personalized Epigenetic Maintenance Approach for AML and MDS Patients after Allogeneic Stem Cell Transplantation
• Enhancing Knowledge Translation and Exchange through Multidisciplinary Case Conferencing Involving Primary and Specialty Care: A Feasibility Study Proposal
• Genomic Path Study (GPS) Feasibility Study - University Health Network, Site 1 (Lead)
• Genomic Pathway Study (UHN)
• Health Services Research Program - Sunnybrook Health Sciences Centre, Site 1 (Lead)
• Herpes virus based oncolytic viruses for cancer therapy
• High Impact Clinical Trials Program (HICT) - Translational Research Team (TRT)
• Imaging Pipeline Platform - Centre For Probe Development and Commercialization, Site 2 (Partner)
• Imaging Pipeline Platform Program - Equipment Award for John Valliant "Molecular Breast Imaging Camera"
• Imaging Pipeline Platform Program - Equipment Award for John Valliant "Probe Development and Production"
• Imaging With 111In-Pertuzumab to predict response to Trastuzumab in HER2 Positive Metastatic Breast (McM)
• Inhibitors of mitochondrial glycerophoshate dehydrogenase
• Interaction between conventional cancer therapy and gene-based cancer vaccines
• Investigator Award for Dr. Rosalyn Juergens
• Molecular Imaging Agents for Breast Cancer Diagnosis and Research
• New MI Probes for Prostate Cancer Detection, Staging and Guidance
• Novel Positron Emission Mammography (PEM) Radiotracer Development
• One Millimetre Cancer Challenge
• One Millimetre Cancer Challenge - McMaster University, Site 6 (Partner)
• Ontario Regional BioTherapeutics (ORBiT) Program - Ottawa Health Research Institute, Site 1 (Lead)
• Ontario Regional BioTherapeutics (ORBiT) Program - Ottawa Health Research Institute, Site 1 (Lead)
• Ontario Regional BioTherapeutics (ORBiT) Program Equipment Award - McMaster University, Site 2 (Partner)
• Optimizing targeted cancer immunotherapy by segregating antitumor function from autoimmune pathogenesis
• Partial Salary Support Award for Dr. Greg Pond
• Probe Development
• Prostate Cancer, Active Surveillance Magnetic Resonance Imaging Study Trial (ASIST TRIAL)
• Salary Support Award for Dr. Greg Pond
• Salary Support Award for Dr. Greg Pond
• Smarter prostate imaging and interventions: DEVELOP - new MI probes for prostate cancer detection
• Stratified False Discovery Rate (SFDR) Software for High Impact Clinical Trials (HICT)-BOLD-PET-MAC - McMaster University
• The Immuno- and Bio-therapies Program
• To identify new therapeutic strategies for acute leukemia by targeting the microenvironment and leukemia niche
• uPA: a multimodal and general-purpose tumour probe for imaging, biopsy and surgical guidance. Metastatic potential imaging by targeting uPA